VTX958 versus placebo para el tratamiento de la psoriasis moderada a grave (Serenity PsO)
Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de VTX958 en participantes con psoriasis de moderada a grave
This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.
The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Fredericton, Canadá
- Local Site # 124012
-
Mississauga, Canadá
- Local Site # 124010
-
Montreal, Canadá
- Local Site # 124002
-
North Bay, Canadá
- Local Site # 124004
-
Oshawa, Canadá
- Local Site # 124011
-
Peterborough, Canadá
- Local Site # 124007
-
Québec, Canadá
- Local Site # 124008
-
Toronto, Canadá
- Local Site # 124005
-
Windsor, Canadá
- Local Site # 124006
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35205
- Local Site # 840012
-
Birmingham, Alabama, Estados Unidos, 35244
- Local Site # 840006
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Local Site # 840028
-
-
Arkansas
-
Bryant, Arkansas, Estados Unidos, 72022
- Local Site # 840032
-
North Little Rock, Arkansas, Estados Unidos, 72117
- Local Site # 840041
-
-
California
-
Fountain Valley, California, Estados Unidos, 92708
- Local Site # 840031
-
Lomita, California, Estados Unidos, 90717
- Local Site # 840026
-
Santa Rosa, California, Estados Unidos, 95405
- Local Site # 840019
-
Sherman Oaks, California, Estados Unidos, 91403
- Local Site # 840003
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33486
- Local Site # 840040
-
Doral, Florida, Estados Unidos, 33122
- Local Site # 840011
-
Hialeah, Florida, Estados Unidos, 33012
- Local Site # 840023
-
Miami Lakes, Florida, Estados Unidos, 33104
- Local Site # 840021
-
North Miami Beach, Florida, Estados Unidos, 33162
- Local Site # 840044
-
Ocala, Florida, Estados Unidos, 34470
- Local Site # 840010
-
Tampa, Florida, Estados Unidos, 33607
- Local Site # 840004
-
Tampa, Florida, Estados Unidos, 33613
- Local Site # 840001
-
West Palm Beach, Florida, Estados Unidos, 33406
- Local Site # 840045
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Local Site # 840029
-
-
Indiana
-
Clarksville, Indiana, Estados Unidos, 47129
- Local Site # 840035
-
Indianapolis, Indiana, Estados Unidos, 46250
- Local Site # 840005
-
Plainfield, Indiana, Estados Unidos, 46168
- Local Site # 840030
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40241
- Local Site # 840013
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Local Site # 840022
-
-
Massachusetts
-
Brighton, Massachusetts, Estados Unidos, 02135
- Local Site # 840008
-
-
Michigan
-
Bay City, Michigan, Estados Unidos, 48706
- Local Site # 840016
-
Fort Gratiot, Michigan, Estados Unidos, 48059
- Local Site # 840007
-
Troy, Michigan, Estados Unidos, 48084
- Local Site # 840002
-
-
Minnesota
-
New Brighton, Minnesota, Estados Unidos, 55112
- Local Site # 840034
-
-
Missouri
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Local Site # 840024
-
-
New Hampshire
-
Portsmouth, New Hampshire, Estados Unidos, 03801
- Local Site # 840027
-
-
North Carolina
-
Wilmington, North Carolina, Estados Unidos, 28405
- Local Site # 840042
-
-
Ohio
-
Mason, Ohio, Estados Unidos, 45040
- Local Site # 840037
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97223
- Local Site # 840009
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57702
- Local Site # 840038
-
-
Tennessee
-
Murfreesboro, Tennessee, Estados Unidos, 37130
- Local Site # 840015
-
-
Texas
-
Pflugerville, Texas, Estados Unidos, 78660
- Local Site # 840039
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99202
- Local Site # 840014
-
-
-
-
-
Bialystok, Polonia
- Local Site # 616015
-
Bialystok, Polonia
- Local Site # 616016
-
Katowice, Polonia
- Local Site # 616001
-
Krakow, Polonia
- Local Site # 616014
-
Lodz, Polonia
- Local Site # 616004
-
Lublin, Polonia
- Local Site #616010
-
Mikołów, Polonia
- Local Site # 616011
-
Nowa Sól, Polonia
- Local Site # 616009
-
Ostrowiec Świętokrzyski, Polonia
- Local Site # 616003
-
Poznan, Polonia
- Local Site # 616008
-
Szczecin, Polonia
- Local Site # 616007
-
Szczecin, Polonia
- Local Site # 616013
-
Warsaw, Polonia
- Local Site # 616005
-
Wroclaw, Polonia
- Local Site # 616002
-
Wroclaw, Polonia
- Local Site # 616006
-
Wroclaw, Polonia
- Local Site # 616018
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female participant aged 18 years or older.
- History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
- Has had stable psoriasis conditions for at least 3 months before screening.
- Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
- Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
- Deemed by the investigator to be eligible for phototherapy or systemic therapy.
- Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.
Exclusion Criteria:
- Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
- Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
- History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
- Participant is known to have immune deficiency or is immunocompromised.
- Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics).
Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.
- Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], Janus kinase [JAK] inhibitors, or tar) within 2 weeks prior to Day 1.
- Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
- Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
- Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
- Participant has received treatment with an investigational or marketed TYK2 inhibitor.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: VTX958 300 mg BID (Placebo Controlled)
Participants received one 300 milligram (mg) VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1. |
VTX958 administered orally |
|
Experimental: VTX958 225 mg BID (PC)
Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1. |
VTX958 administered orally |
|
Experimental: VTX958 300 mg QD (PC)
Participants received 300 mg VTX958 tablet administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1. |
VTX958 administered orally |
|
Experimental: VTX958 50 mg BID (PC)
Participants received 50 mg VTX958 tablet administered orally BID and matching placebo tablets administered orally BID to maintain the blind in Period 1. |
VTX958 administered orally |
|
Comparador de placebos: Placebo BID (PC)
Participants received placebo tablets matched to VTX958, administered BID to maintain the blind in Period 1. |
Placebo administered orally |
|
Experimental: Long Term Extension Period (LTE): VTX958 300 mg BID
Participants who received 300 mg VTX958 dose administered orally BID in Period 2. |
VTX958 administered orally |
|
Experimental: LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID
Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2. |
VTX958 administered orally |
|
Experimental: LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD
Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2. |
VTX958 administered orally |
|
Experimental: LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID
Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2. |
VTX958 administered orally |
|
Experimental: Open Label Extension (OLE): VTX958 300 mg BID
Participants who received 300 mg VTX958 dose administered orally BID in Period 3. |
VTX958 administered orally |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Periodo de tiempo: Week 16
|
Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo. |
Week 16
|
|
Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958
Periodo de tiempo: Baseline up to week 16
|
The number of participants with TEAEs and SAEs observed during the study of VTX958. A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated). An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences:
|
Baseline up to week 16
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16
Periodo de tiempo: Week 16
|
Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur
|
Week 16
|
|
Period 1: Change From Baseline in PASI Score at Week 16
Periodo de tiempo: Baseline, Week 16
|
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. |
Baseline, Week 16
|
|
Period 1: Percent Change From Baseline in PASI Score at Week 16
Periodo de tiempo: Baseline, Week 16
|
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. |
Baseline, Week 16
|
|
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16
Periodo de tiempo: Week 16
|
Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. |
Week 16
|
|
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16
Periodo de tiempo: Week 16
|
Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. |
Week 16
|
|
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks
Periodo de tiempo: Baseline, Week 16
|
The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity. |
Baseline, Week 16
|
|
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16
Periodo de tiempo: Baseline, Week 16
|
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement. |
Baseline, Week 16
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Snehal Naik, PhD, Ventyx Biosciences, Inc
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- VTX958-201
- 2022-002887-59 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .